Cost-effectiveness of prasugrel in a US managed care population.

@article{Mauskopf2012CosteffectivenessOP,
  title={Cost-effectiveness of prasugrel in a US managed care population.},
  author={Josephine A. Mauskopf and Jonathan B. Graham and Jay Patrick Bae and Krishnan Ramaswamy and Anthony J Zagar and Elizabeth A. Magnuson and David Jacques Cohen and Eric S. Meadows},
  journal={Journal of medical economics},
  year={2012},
  volume={15 1},
  pages={
          166-74
        }
}
OBJECTIVE Decision-makers in the US may be interested in the applicability to their populations of cost-effectiveness results generated from clinical trial populations. METHODS An economic model estimating the cost-effectiveness of prasugrel plus aspirin relative to clopidogrel plus aspirin for patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) was developed from a managed care organization (MCO) perspective. The model estimated 15-month… CONTINUE READING
BETA
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
SHOWING 1-8 OF 8 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 20 REFERENCES

Physicians’ fee reference, 28th edn. Milwaukee, WI: Yale Wasserman, DMD

  • Yale Wasserman
  • Medical Publishers Ltd,
  • 2011

of Labor, Bureau of Labor Statistics

  • US Departmen
  • Consumer Price Index— all urban consumers…
  • 2010

Hospital contracting trends and implications for adoption and use of new health technologies

  • E Faulkner, J Mauskopf, J. Bae
  • J Manag Care Med
  • 2009

Similar Papers

Loading similar papers…